Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Investing Activities (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Cash from Investing Activities for 12 consecutive years, with $439000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 97.58% year-over-year to $439000.0, compared with a TTM value of -$30.2 million through Sep 2025, down 130.99%, and an annual FY2024 reading of $99.7 million, up 166.17% over the prior year.
  • Cash from Investing Activities was $439000.0 for Q3 2025 at CytomX Therapeutics, up from -$76.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $99.8 million in Q4 2022 and bottomed at -$146.6 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is $1.3 million, with a median of $9.7 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities surged 40842.04% in 2022, then plummeted 19824.18% in 2023.
  • Year by year, Cash from Investing Activities stood at -$245000.0 in 2021, then soared by 40842.04% to $99.8 million in 2022, then tumbled by 87.11% to $12.9 million in 2023, then rose by 17.64% to $15.1 million in 2024, then tumbled by 97.1% to $439000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for CTMX at $439000.0 in Q3 2025, -$76.4 million in Q2 2025, and $30.6 million in Q1 2025.